August 28, 2025

Neurostimulated Tears

Targeting TRPM8: a novel therapeutic angle for Dry Eye Disease

The Ophthalmologist

August 22, 2025

FDA Agreement for AXPAXLI Registrational Trial

Ocular Therapeutix secures FDA agreement on NPDR trial design

The Ophthalmologist

August 22, 2025

Osteoporosis and AMD Risk

Study explores the link between osteoporosis and AMD with data taken from NHANES

The Ophthalmologist

August 21, 2025

FDA Grants RMAT to VeonGen Gene Therapy

VG801 is being developed for Stargardt disease and other ABCA4-related retinal disorders.

Retinal Physician

August 21, 2025

Nicox Reports Positive Phase 3 Denali Trial Data

In the phase 3 study, NCX 470 met the primary endpoint of noninferiority to latanoprost in lowering IOP.

Ophthalmology Management

August 20, 2025

Wide Disparities in IRD Diagnosis

Nationwide study shows jump in prevalence of IRDs

The Ophthalmologist

August 17, 2025

FDA Affirms Safety of PFAS-Based Materials in Medical Devices

PFAS used in medical devices are different from the small-molecule PFAS that have been linked to environmental and health concerns.

Contact Lens Spectrum

August 14, 2025

Three Lifestyle Behaviors Linked with Cataract Development

Poor sleep, low physical activity (PA), and high sedentary behavior (SB) were found to be both independently and jointly linked with an increased risk of cataract, according to a recent cross-sectional analysis, published in BMC Medicine.

Optometric Management

August 12, 2025

Ocular Therapeutix Announces FDA Approves NPDR Trial Plan for OTX-TKI

A Special Protocol Assessment (SPA) establishes a regulatory path for Ocular Therapeutix’s Axpaxli in diabetic eye disease.

Ophthalmology Management